Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-Small Cell Lung Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Perspective (2019-2030)
2.2 Drugs for Non-Small Cell Lung Cancer Growth Trends by Region
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Non-Small Cell Lung Cancer Market Dynamics
2.3.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
2.3.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue (2019-2024)
3.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Non-Small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-Small Cell Lung Cancer Revenue in 2023
3.5 Drugs for Non-Small Cell Lung Cancer Key Players Head office and Area Served
3.6 Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
3.7 Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2025-2030)
5 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
6.2 North America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
6.4 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
7.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
9.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
9.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Menarini
11.3.1 Menarini Company Detail
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.3.5 Menarini Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Detail
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.5.5 Ziopharm Oncology Recent Development
11.6 Alchemia
11.6.1 Alchemia Company Detail
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.6.5 Alchemia Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.7.5 Amgen Recent Development
11.8 Apotex
11.8.1 Apotex Company Detail
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.8.5 Apotex Recent Development
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Detail
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.9.5 BioMarin Pharmaceutical Recent Development
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Detail
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.10.5 CellAct Pharma Recent Development
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Detail
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.11.5 Cerulean Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Detail
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.12.5 Cipla Recent Development
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Detail
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.13.5 Cornerstone Pharmaceuticals Recent Development
11.14 Curis
11.14.1 Curis Company Detail
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.14.5 Curis Recent Development
11.15 CytRx
11.15.1 CytRx Company Detail
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.15.5 CytRx Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Detail
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.16.5 Eli Lilly Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Detail
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.17.5 Exelixis Recent Development
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Detail
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.18.5 Fresenius Kabi Recent Development
11.19 Genentech
11.19.1 Genentech Company Detail
11.19.2 Genentech Business Overview
11.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
11.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.19.5 Genentech Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Detail
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Hospira
11.21.1 Hospira Company Detail
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.21.5 Hospira Recent Development
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Detail
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.22.5 Intas Pharmaceuticals Recent Development
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Detail
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.23.5 Karyopharm Therapeutics Recent Development
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Detail
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.24.5 Kyowa Hakko Kirin Recent Development
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Detail
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.25.5 Ligand Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details